AIDS patients have increased surfactant protein D but normal mannose binding lectin levels in lung fluid by Jambo, Kondwani C et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
Respiratory Research
Open Access Research
AIDS patients have increased surfactant protein D but normal 
mannose binding lectin levels in lung fluid
Kondwani C Jambo1, Neil French2, Ed Zijlstra3 and Stephen B Gordon*4
Address: 1Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi, 2Wellcome Trust/LEPRA Karonga Prevention Study, 
London School of Hygiene and Tropical Medicine, Chilumba, Malawi, 3Department of Medicine, University of Malawi College of Medicine, 
Blantyre, Malawi and 4Liverpool School of Tropical Medicine, Liverpool, UK
Email: Kondwani C Jambo - kjambo@mlw.medcol.mw; Neil French - n.french@lshtm.ac.uk; Ed Zijlstra - eezijlstra@malawi.net; 
Stephen B Gordon* - sbgordon@liverpool.ac.uk
* Corresponding author    
Abstract
Background: Surfactant protein D (SP-D) and Mannose Binding Lectin (MBL) are collectins that
have opsonic and immunoregulatory functions, are found in lung fluid and interact with the human
immunodeficiency virus (HIV). We compared collectin levels in lung fluid and serum from HIV
infected and normal subjects to determine if alterations in lung collectin levels were associated with
HIV infection and might result in increased susceptibility to other pulmonary infections.
Methods:  Blood and bronchoalveolar lavage samples were collected from 19 HIV-infected
individuals and 17 HIV-uninfected individuals, all with normal chest X ray at time of study. HIV viral
loads and peripheral blood CD4+ T cell counts were measured in all subjects. SP-D was measured
in lung fluid, and MBL in both lung fluid and serum.
Results: SP-D levels were not significantly different in lung fluid from HIV-uninfected (median
406.72 ng/ml) and HIV-infected individuals with high CD4 count (CD4 >200) (median 382.60 ng/
ml) but were elevated in HIV-infected individuals with low CD4 count (median 577.79 ng/ml;
Kruskall Wallis p < 0.05). MBL levels in serum were not significantly different between HIV-
uninfected and HIV-infected individuals (median 1782.70 ng/ml vs 2639.73 ng/ml) and were not
detectable in lung fluid.
Conclusion: SP-D levels are increased in lung fluid from AIDS patients but not in patients with
early HIV infection. MBL levels are not altered by HIV infection or AIDS. There is no evidence that
altered pulmonary collectin levels result in susceptibility to infection in these patients.
Background
Surfactant protein D (SP-D) and mannose binding lectin
(MBL) are members of the human collectin system. The
collectins are a group of molecules characterised by a col-
lagenous region and a lectin (carbohydrate-binding)
domain which together give the members structural and
functional similarity[1]. The collectins function in innate
immunity as opsonins and agglutinins but also have
important pro- and anti-inflammatory immunomodula-
tory functions[2]. Surfactant protein D is produced
mainly in the lung by alveolar type II cells and bronchi-
olar epithelial cells, but has also been reported at other
mucosal surfaces[3]. Mannose binding lectin is produced
in the liver as an acute phase protein which may leak from
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the systemic circulation at the site of inflammation in the
lungs, and provide an optional host defence mecha-
nism[4].
Alterations in collectin levels are associated with suscepti-
bility to pulmonary infection. Levels of SP-D are
decreased in bronchoalveolar lavage fluid of cystic fibrosis
patients and relative collectin deficiency is inversely
related to inflammation in these patients[5]. SP-D is criti-
cal in modulating responses to respiratory viral infec-
tions[6] and bacterial pneumonia[7]. It is present in
serum of healthy adults ranging from 158 – 3711 ng/ml
but SP-D in serum is considered to reflect damage to or
response from epithelial cells to inflammation[7].
Reduced levels of MBL in serum are associated with
meningococcal invasion through the respiratory tract[8,9]
and MBL was recently shown to be a critical determinant
of macrophage ingestion of meningococci[10]. MBL was
present in bronchoalveolar lavage samples from patients
with pneumonia at concentrations ranging from 0.011 to
0.078 mg/ml but none was found in bronchoalveolar lav-
age from healthy adults[11].
SP-D and MBL play an important role in defence against
HIV infection. SP-D binds to the HIV surface protein
gp120 and has significant HIV-binding and inhibitory
activities[3]. SP-D expression has recently been measured
in both respiratory and non-respiratory mucosa including
the oral cavity and female genital tract[12,13] suggesting
a possible role in sexual or vertical transmission of HIV.
SP-D inhibits HIV infectivity at significantly lower con-
centrations than MBL[3]. Increased susceptibility to HIV
infection in patients with MBL insufficiency or protection
from HIV in those with high MBL levels has been
reported[14,15] but the effect of reduced levels of MBL on
HIV disease progression are controversial[16,17]. MBL
initiates complement activation[18] and can also inhibit
DC-SIGN-mediated transfer of HIV from dendritic cells to
T cells[19].
Our hypothesis was that reduced levels of collectins in
BAL might result in increased susceptibility to pneumonia
among AIDS patients. Our goal in this study was to deter-
mine if HIV status (stratified by CD4 count) was associ-
ated with altered levels of collectins in BAL and serum.
Methods
Subject recruitment and sample collection
Adult Malawians were recruited by advertisement and
gave written informed consent to participate in a study of
pulmonary immune responses to infection. This study
included bronchoscopy with lavage, serum sampling and
HIV testing. This study was approved by the Liverpool
School of Tropical Medicine Research Ethics Committee
and the College of Medicine Research Ethics Committee
of the University of Malawi.
Patients attended recruitment clinic when venous blood
was collected. Bronchoscopy with lavage was carried out a
few days later as previously described[20]. Briefly, a fibre-
optic bronchoscope was wedged in a sub-segmental bron-
chus of the right middle lobe and 200 ml of warmed
sterile saline introduced in 4 aliquots. Bronchoalveolar
lavage (BAL) obtained by this method typically yields 120
ml of cellular fluid. BAL and venous blood samples were
transferred on ice immediately to the laboratory and cen-
trifuged to remove the cellular pellet. Supernatant fluid
and serum obtained from venous blood were stored at -
80°C for future assay.
Laboratory assays
Serum HIV viral loads and CD4+ T cell counts were deter-
mined by Amplicor HIV-1 Monitor Test version 5.0 and
Becton Dickinson FACS Count, respectively.
Measurement of SP-D in BAL was done using an SP-D
Sandwich ELISA kit (BioVender GmbH, Germany). The
Standards and Quality Controls used in this kit are both
human recombinant protein based. The Assay was done
in accordance with the manufacturer's instructions.
Measurement of MBL in serum and BAL was done using
an MBL ELISA kit (Sanquin, Netherlands). The kit has a
minimum detection level of 9.0 ng/mL and a measurable
concentration range of 9.0 to 350 ng/mL. The Assay was
done in accordance with the manufacturer's instructions.
Statistical Analysis
HIV-infected patients were stratified into two groups
according to peripheral blood CD4+ T lymphocyte cell
count greater or less than 200 cells/ml. This corresponds
to a clinical diagnosis of AIDS. We compared levels of SP-
D and MBL in BAL and serum by HIV status using Mann
Whitney test and Kriskall Wallis test. The results were
reported as median with interquartile ranges. Intercooled
Stata 9.2 was used to perform all the statistical operations
in this study. All the graphs in this study were produced
using GraphPad Prism 5.00.
Results
Subjects
Blood and BAL samples were collected with informed
consent from 19 HIV-infected and 17 HIV-uninfected
individuals, all of whom were healthy at the time of bron-
choscopy and had a normal chest X ray. The demographic
and clinical characteristics of the three groups are summa-
rised in Table 1. There was no significant difference in age
distribution between the groups. There was a higher mean
HIV viral load in both the serum and BAL of subjects withRespiratory Research 2007, 8:42 http://respiratory-research.com/content/8/1/42
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CD4 counts less than 200 cells/μl (clinical AIDS) than in
HIV infected subjects with higher CD4 counts. None of
the HIV infected subjects was on anti-retroviral therapy at
the time of the study. Three subjects with AIDS were cur-
rent cigarette smokers of 3, 5 and 20 cigarettes per day
(1.5, 5 and 15 pack-years) and two normal subjects were
current smokers of 5 and 6 cigarettes per day (both 3 pack-
years). One HIV infected subject with a normal CD4
count (greater than 500 cells/μl) had stopped smoking in
1971 (1.5 pack-years).
Surfactant Protein D in lung fluid during HIV infection
The levels of SP-D in BAL of HIV positive individuals were
compared with levels of SP-D in BAL of HIV-uninfected
individuals. These levels were not significantly different
with median SP-D in HIV uninfected 406.72 ng/ml com-
pared to 463.05 in HIV infected (Mann Whitney p = 0.32)
(Figure 1a). We also compared the levels of SP-D among
normal subjects, HIV positive subjects with CD4 count
>200 cells/μl and patients with AIDS (CD4 count <200
cells/μl). SP-D levels were significantly higher in AIDS
patients (median 577.79 ng/ml) compared to normal
subjects (median 406.72 ng/ml; Kruskall Wallis p = 0.03)
or HIV-infected individuals with CD4 count greater than
200 cells/μl (median 382.60 ng/ml; Kruskall Wallis p =
0.05) (Figure 1b).
As it has been reported that SP-D has significant HIV-
binding and inhibitory activities exceeding MBL[12], we
investigated the possibility that high levels of SP-D were
associated with low viral loads in BAL. SP-D levels were
found to have a weak relationship with BAL viral loads (p
< 0.05, r2 = 0.26). We also compared SP-D concentration
to CD4 count, it was found that there was a weak relation-
ship between the two variables (p < 0.05, r2 = 0.30)
Mannose Binding Lectin in serum and BAL during HIV 
infection
MBL levels in serum compared by HIV status were not sig-
nificantly different as shown in Figure 2a (median MBL in
normal 1782.70 ng/ml compared to 2639.73 ng/ml in
HIV infected; Mann Whitney p = 0.58). We also compared
the levels of MBL among normal subjects, HIV positive
subjects with CD4 count > 200 and AIDS patients (CD4
count <200 cells/μl). MBL levels were not significantly dif-
ferent among these three groups as shown in Figure 2b
(median MBL in normals 1782.70 ng/ml vs HIV positive
individuals (CD4 count >200 cells/μl) 2291.73 ng/ml vs
AIDS patients 2651.74 ng/ml; Kruskall Wallis p = 0.70).
MBL levels in BAL were below the lower limit of detection
in all samples. Using extrapolated data, MBL levels in BAL
compared by HIV status showed no significant difference
(median MBL in normal 0.283 ng/ml compared to 0.401
ng/ml in HIV infected; Mann Whitney p = 0.06). MBL lev-
els in BAL showed a significant correlation with MBL lev-
els in serum in both HIV-infected and HIV-uninfected
individuals (p < 0.05). MBL levels in serum or BAL in HIV
infected patients did not show significant correlation with
CD4 count or HIV viral load in either plasma or BAL (p >
0.05).
Discussion
In this study, levels of SP-D and MBL in BAL and serum
collected from HIV infected patients were not different
from those in normal subjects. Among HIV infected
patients, patients with AIDS had a higher SP-D than
patients with higher CD4 counts. MBL levels in BAL were
very low, and correlated with serum levels of MBL, which
were not altered by HIV status or clinical AIDS.
Previous studies have shown that SP-D deficiency is asso-
ciated with increased respiratory infection[7] and is asso-
ciated with increased airway inflammation[5]. There was
no evidence in this study to suggest that low SP-D level is
a factor in the susceptibility of HIV infected patients to res-
piratory infection[21], or that lack of SP-D contributes to
the pulmonary inflammation that is a feature of
AIDS[22,23]. SP-D has been shown to bind to HIV enve-
lope protein gp120 and inhibit HIV replication[3] so the
increased SP-D levels seen in our subjects with AIDS may
be an appropriate response, although we were not able to
demonstrate a relationship between SP-D level and BAL
HIV viral load. SP-D suppresses lymphocyte function by
inhibiting T lymphocyte proliferation [24] therefore a
decrease in CD4 count might be secondary to an increase
in SP-D levels but we did not detect this association. Our
patients were healthy and had normal chest radiographs
but the increased SP-D seen in AIDS patients in this study
is consistent with recent observations made of intensive
Table 1: Demographic and clinical features of subjects in the study
Clinical feature Normal HIV infected (CD4 >200 cells/ul) AIDS patients (CD4<200 cells/ul)
Gender M:F 17 : 2 8 : 2 6 : 1
Age, Mean (± SD), years 30 (9.9) 33.6 (9.4) 34.5 (7.2)
CD4+ T cell count, mean (range), cells/μl 606 (512–978) 493 (368–675) 149 (46–179)
Plasma HIV-1 load, mean (range) copies/ml 0 1.4 × 105 (0.008–4.0 × 105)2 . 3  ×  1 0 5 (0.3–6.6 ×105)
BAL Fluid HIV-1 load, mean (range) copies/ml 0 129 (0–670) 175(0–550)
Abbreviations: BAL = Bronchoalveolar Lavage, SD = Standard DeviationRespiratory Research 2007, 8:42 http://respiratory-research.com/content/8/1/42
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care patients with pneumocytsis pneumonia in Ger-
many[25].
MBL is a serum collectin that is found in lung at very low
levels except in conditions of severe inflammation such as
those that accompany pneumonia[11]. MBL leaks into the
alveolar space in conditions of inflammation but levels do
not increase as an acute phase protein[26]. We found that
MBL levels were detectable but were not raised in BAL
from HIV infected subjects or in subjects with AIDS, sug-
Levels of MBL in serum of both HIV-uninfected and HIV pos- itive individuals Figure 2
Levels of MBL in serum of both HIV-uninfected and 
HIV positive individuals. The bars represent median and 
interquartile range. a). The analysis was performed on 19 
HIV-uninfected and 17 HIV Positive subjects. b). The analysis 
was performed on 19 HIV-uninfected, 10 HIV Positive with 
CD4 count > 200 and 7 AIDS patients (CD4 count < 200).
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Levels of SP-D in BAL of both HIV-uninfected and HIV posi- tive individuals Figure 1
Levels of SP-D in BAL of both HIV-uninfected and 
HIV positive individuals. The bars represent median and 
interquartile range. a). The analysis was performed on 19 
HIV-uninfected and 16 HIV Positive subjects. b). The analysis 
was performed on 19 HIV-uninfected, 10 HIV Positive with 
CD4 count > 200 and 6 AIDS patients (CD4 count < 200).
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gesting that the vascular integrity of the lung in these sub-
jects was intact. We were able to correlate the MBL levels
found in BAL with those in serum, both for HIV infected
and normal subjects. We found no difference in MBL lev-
els when we compared serum from normal subjects, HIV
infected and AIDS patients. This differs from a study
which showed a higher level of MBL in HIV infected
patients[27] but is consistent with studies that showed no
association between MBL level and either HIV infection,
disease progression or AIDS[16,17]. Like SP-D, MBL binds
HIV viral gp120 and can activate complement but we did
not detect any association of MBL level with increased
HIV viral load or AIDS.
Conclusion
There was no evidence that susceptibility to infection or
inflammation in the lungs of AIDS patients was due to
altered levels of the collectins SP-D or MBL.
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